BLNP 005
Alternative Names: BLNP-005Latest Information Update: 28 Mar 2022
At a glance
- Originator BL-&-H
- Class Antineoplastics; Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Erythrodysaesthesia
- Discontinued Ovarian cancer
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for clinical-Phase-Unknown development in Erythrodysaesthesia in South Korea
- 18 Feb 2019 Clinical trials in Erythrodysaesthesia in South Korea (unspecified route) (BL & H pipeline, February 2019)
- 18 Feb 2019 Discontinued - Clinical-Phase-Unknown for Ovarian cancer in South Korea (unspecified route) (BL & H pipeline, February 2019)